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N-methyl-D-aspartate (NMDA) receptor antagonists administered to healthy humans
results in schizophrenia-like symptoms, which preclinical research suggests are
due to glutamatergically altered brain oscillations. Here, we examined resting-state
electroencephalographic activity in 21 healthy volunteers assessed in a placebo-
controlled, double-blind, randomized study involving administration of either a saline
infusion or a sub-anesthetic dose of ketamine, an NMDA receptor antagonist.
Frequency-specific current source density (CSD) was assessed at sensor-level and
source-level using eLORETA within regions of interest of a triple network model of
schizophrenia (this model posits a dysfunctional switching between large-scale Default
Mode and Central Executive networks by the monitor-controlling Salience Network).
These CSDs were measured in each session along with subjective symptoms as
indexed with the Clinician Administered Dissociative States Scale. Ketamine-induced
CSD reductions in slow (delta/theta and alpha) and increases in fast (gamma)
frequencies at scalp electrode sites were paralleled by frequency-specific CSD changes
in the Default Mode, Central Executive, and Salience networks. Subjective symptoms
scores were increased with ketamine and ratings of depersonalization in particular
were associated with alpha CSD reductions in general and in specific regions of
interest in each of the three networks. These results tentatively support the hypothesis
that pathological brain oscillations associated with hypofunctional NMDA receptor
activity may contribute to the emergence of the perceptual/dissociate symptoms of
schizophrenia.
Keywords: ketamine, N-methyl-D-aspartate, brain oscillations, electroencephalography, psychosis,
schizophrenia
INTRODUCTION
Blockade of glutamate N-methyl-D-aspartate receptors (NMDAR) by a subanesthetic dose of
ketamine in humans transiently induces negative, positive and cognitive symptoms similar to
those found in schizophrenia (SZ). Together with findings in animals of behavioral, biochemical,
and electrophysiological alterations with NMDAR antagonists, convergent genetic, molecular and
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neuroimaging evidence points to NMDAR hypofunction in
SZ (Javitt, 2012; Javitt et al., 2012). This supports use of the
ketamine challenge as a pharmacological approach to generating
insights into SZ symptoms and their underlying pathophysiologic
processes (Frohlich and Van Horn, 2014).
Oscillatory brain activity is considered a fundamental process
in the temporal coordination of circuits linked to perceptual,
cognitive, and emotional functions. This brain activity, as
measured by the amplitude/power of electroencephalographic
(EEG) rhythms, is increasingly seen as an indicator of intrinsic
brain function when assessed during stimulation/task-free states
(Spencer, 2014). Further, this activity has been found to be altered
in SZ and to vary with symptomatology (Boutros et al., 2008,
2014; Moran and Hong, 2011; Galderisi et al., 2014). Aberrant
“resting-state” spectral EEG profiles in psychosis have invariably
shown increased activity in low frequency (delta, theta) EEG
and magnetoencephalographic (MEG) rhythms (Fehr et al., 2003;
Boutros et al., 2008; Venables et al., 2009; Uhlhaas and Singer,
2010; Moran and Hong, 2011; Ranlund et al., 2014) which
have been found specifically evidenced in chronic SZ patients
(Sponheim et al., 1994, 2000; Narayanan et al., 2014), their first-
degree relatives (Narayanan et al., 2014) and first-episode SZ
patients (Sponheim et al., 2000), but not in individuals at-risk
for psychosis (Ranlund et al., 2014). Spontaneous alpha activity,
which predominates in healthy individual’s EEG, is significantly
diminished in chronic SZ patients (though unaffected in some
studies), with varying findings that depend on scalp region,
and whether slower or faster frequencies are examined within
this band (Sponheim et al., 1994, 2000; Knyazeva et al., 2008;
Hong et al., 2012; Narayanan et al., 2014; Goldstein et al., 2015;
Kim et al., 2015). Similar inconsistencies are evident with beta
rhythms, with chronic patients showing either no abnormalities
(Wada et al., 1994; Kam et al., 2013; Kim et al., 2015) or increased
activity (Sponheim et al., 1994; Venables et al., 2009; Narayanan
et al., 2014). As with delta/theta findings (Galderisi et al., 2009),
these inconsistencies can be partially attributed to the effects of
chronicity, medication and patient symptomatology (Czobor and
Volovka, 1992; Merlo et al., 1998; Knott et al., 2001; Cerdán et al.,
2005; Venables et al., 2009; Moran and Hong, 2011). The recent
interest in resting gamma activity, increased in some (Czobor
and Volovka, 1992; Merlo et al., 1998; Knott et al., 2001; Cerdán
et al., 2005; Kam et al., 2013; Kocsis et al., 2013; Tikka et al.,
2013, 2014, 2015) but not all EEG or MEG studies (Sponheim
et al., 1994) of SZ patients (Rutter et al., 2009; Fuggetta et al.,
2014; Hirano et al., 2015) is of particular interest both because
of its purported role in feature binding and coordination of local
neuronal populations, and because these rhythms are in part
dependent on the activity of Parvalbumin-containing GABAergic
cortical inhibitory interneurons, which are diminished in SZ
patients and subject to NMDAR modulation from excitatory
pyramidal cells (Lee et al., 2003; Herrmann and Dermirlap, 2005;
Sun et al., 2011; Gandal et al., 2012; Lewis et al., 2012; Cohen
et al., 2015). Integrative brain functions, however, are modulated
through multiple oscillatory processes in different frequency
bands, each with differing neuropharmacological sensitivities.
As such, the study of the full frequency spectrum and its
pharmacological basis is critical for deciphering the complex
electrophysiologic abnormalities in SZ patients (Moran and
Hong, 2011).
Electrophysiological recordings in animals with NMDAR
antagonists such as ketamine and MK-801 recreate some of
the background spontaneous EEG features of SZ (Hunt and
Kasicki, 2013). Consistent with patient findings, increases in
delta are dose-dependent and evident in cortical and subcortical
(hippocampus, thalamus) regions. Theta frequency activity also
shows these dose related changes, with power in this band
consistently increased in cortex but reduced in the hippocampus.
Ketamine’s effects on these rhythms in rodents, although
generally augmenting beta and gamma by its actions on PV-
interneurons in multiple cortical regions (Pinault, 2008; Carlén
et al., 2012), vary depending on dose, acute vs chronic treatments,
subcortical region and within-band (slow vs. fast) frequencies
(Pinault, 2008; Roopun et al., 2008; Hakami et al., 2009; Carlén
et al., 2012; Kittelberger et al., 2012; Hunt and Kasicki, 2013;
Kocsis et al., 2013). In humans administered relatively high
(anesthetic) doses of ketamine (∼2 mg/kg), activity is increased
in theta and beta bands and decreased in alpha (Schultz et al.,
1990; Bojak et al., 2013). Sub-anesthetic psychotomimetic bolus
doses of ketamine (0.2–0.5 mg/kg) have also increased theta
and decreased alpha in baseline (pre-stimulus) EEGs (Kochs
et al., 1996). In the only two human resting-state EEG studies to
date, reductions in delta, alpha, and beta (gamma not assessed)
were found with an ultra-low ketamine dose (Knott et al.,
2006), and increases in gamma (other bands not assessed)
were observed with a psychotogenic dose, but relationships
with induced dissociative or psychotic-like symptoms were not
examined (Sanacora et al., 2014). Of the two human resting MEG
studies, subanesthetic ketamine increased gamma in both while
reducing either alpha (Muthukumaraswamy et al., 2015) or beta
(Rivolta et al., 2015).
Ketamine-modulated neuroelectric activity in rodent models
suggest complex-spatiotemporal effects, which vary with
frequency band and cortical area (Lee et al., 2003; Herrmann
and Dermirlap, 2005; Pinault, 2008; Roopun et al., 2008; Moran
and Hong, 2011; Carlén et al., 2012; Gandal et al., 2012; Lewis
et al., 2012; Hunt and Kasicki, 2013; Cohen et al., 2015). Similar
systematic EEG studies on healthy humans of the effects of
subanesthetic, psychotomimetic doses of ketamine on the
generation and cortical distribution of intrinsic brain rhythms
across the frequency spectrum have not been conducted. Thus,
one of our objectives has been to profile the acute effects of
ketamine on the generation and topography of sensor-level
EEG in low and high frequencies using reference-free current
source density (CSD) measures (Nunez and Srinivasan, 2006).
Such reference-free measures avoid problems associated with
reference-dependent EEG indices (Kayser and Teake, 2010);
reference-independent CSD measures reduce volume conduction
from distal sites, sharpen spatial resolution, and are more closely
related to neuronal activity and the strength of underlying
current generators (Nicholson, 1973; Nunez and Srinivasan,
2006; Kayser and Teake, 2010).
A second objective has been the evaluation of the effects
of NMDAR blockade on source-level, electric activity within
Nekovarova et al.’s (2014) recent triple network (TN) model
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of SZ psychopathology. Largely investigated with fMRI (Fox
and Raichle, 2007), but also assessed with PET (Raichle
et al., 2001) and EEG (Chen et al., 2008; Yuan et al., 2012),
brain regions have been shown to be dynamically organized
into functional networks of intercorrelated areas (or “nodes”)
that act together to perform specific tasks (Bressler, 1995).
Of the full repertoire of brain networks, all of which are
continuously and dynamically “active” not only during cognition
but even when at “rest” (Smith et al., 2009), during sleep
(Fukunaga et al., 2006) and under anesthesia (Vincent et al.,
2007), there are three large-scale domain-specific networks
that make up the model which exhibits abnormalities in
SZ (Bressler and Menon, 2010) and depression (Mulders
et al., 2015): the default mode network (DMN), the central
executive network (CEN), and the salience network (SN). This
TN model relies on accumulating neuroimaging evidence in
healthy humans indicating that SN, which is involved in the
orientating of attention to the most homeostatically relevant
(salient) of ongoing extrapersonal (sensory) and intrapersonal
(limbic driven) events (Bressler and Menon, 2010), causally
influences anticorrelated activation of DMN and CEN. Clinical
and cognitive symptoms of SZ are in part attributed to
aberrant switching by the SN between internal processes (i.e.,
self-referential, autobiographical functions) supported by the
DMN and external processes (i.e., attention and processing of
exogenous stimuli) supported by the CEN as a result of a
dysfunctional SN, a system that enables the switch between
various dynamic brain states (Sridharan et al., 2008; Palaniyappan
et al., 2012).
Adopting a region of interest (ROI) approach with exact low
resolution brain electromagnetic tomography (i.e., eLORETA),
which is an electrophysiological neuroimaging method that
allows a reliable source localization of surface level electrical
signals (Pascual-Marqui, 2011; Pascual-Marqui et al., 2011),
we assessed ketamine-induced changes in two key regional
nodes anchoring each of the three large-scale networks:
DMN [ventromedial prefrontal cortex (VMPFC) and posterior
cingulate cortex (PCC)]; CEN [dorsolateral prefrontal cortex
(DLPFC) and posterior parietal cortex (PPC)]; and SN [anterior
cingulate cortex (ACC) and anterior insula (AI)]. Based on
limited human EEG studies with NMDAR antagonists, we
hypothesized that relative to placebo, ketamine administration
in healthy humans would produce SZ-like scalp surface CSD
changes (↑ delta, beta and gamma, and ↓ alpha). Ketamine has
been shown to alter resting SN and DMN function (Bonhomme
et al., 2016) and given the pivotal role of the SN in the
TN model and the available neuroimaging evidence indicating
a primary role of dopamine in the interaction of the SN
with subcortical sites, whilst the within-network activity of
the SN and its interaction with other large-scale networks
is thought to predominantly depend on glutamate/gamma-
aminobutyric acid (GABA) neurotransmission (Palaniyappan
et al., 2012), we expected ketamine to result in band-dependent
CSD alterations within the cortical networks. We further
hypothesized that these sensor- and source-level EEG changes
would be accompanied by dissociative symptoms characteristic
of SZ.
MATERIALS AND METHODS
Participants
A sample of 21 right-hand dominant, male volunteers (mean
age = 21.3 years, ±2.5 SE) were recruited via local media
advertisements. Male volunteers were chosen in order to
avoid any potential confounding effects of menstrually related
hormonal changes on ketamine response. Volunteers underwent
both a psychiatric interview, using both the Structured
Clinical Interview, non-Patient version (SCID-NP) for DMS-IV
(Williams et al., 1992) and the Family Interview for Genetic
Studies (FIGS), (Maxwell, 1992) and a medical exam, including
electrocardiogram and routine blood/urine laboratory tests as
well as using toxicology for drug use. Only healthy individuals
who were medication-free, non-smokers (smoked < 100
cigarettes, none in the past year), reported no neurological
disease, and had no personal or family (first-degree biological
relatives) psychiatric/substance abuse history were included
in the study. The protocol was approved by the Research
Ethics Board of the Royal Ottawa Health Care Group and all
participants provided written informed consent. This study was
conducted in accordance with the Tri-Council Policy Statement
on Ethical Conduct for Research Involving Humans. Participants
were compensated $75 CAD for each of the two test sessions.
Design
Volunteers participated in the test sessions within a randomized,
double-blind design in which half were administered placebo
in the first session and ketamine in the second session, while
the remaining half received treatments in the reverse order.
A minimum 5 days interval separated the two test sessions.
Procedures
Test sessions (beginning 8:00 a.m.) followed overnight abstinence
from food, caffeine, alcohol, and drugs and began with insertion
of an antecubital intravenous line after which, participants
rested for a 45-min adaptation period and EEG electrodes were
positioned on the scalp. A racemic ketamine or saline 0.90% w/v
of NaCl bolus dose was then administered (0.26 mg/kg) over
10 min and was immediately followed by a constant infusion
of 0.65 mg/kg lasting ∼60 min, as per Krystal et al. (1999).
Beginning 10 min after the initiation of the constant infusion, a
3 min EEG recording was collected, after which participants were
evaluated with the Clinician Administered Dissociative States
Scale (CADSS), (Bremner et al., 1998) which has been previously
shown to be sensitive to ketamine administration (Krystal et al.,
1994). The scale consists of 19 self-report items, (scored as
0 = not at all; 1 = slightly; 2 = moderately; 3 = considerably;
4 = extremely), which yielded three subjective subscale scores
(amnesia, depersonalization, and derealisation) and it also has
similarly scored 8 clinician rated items that result in one observer
rated score.
EEG Recording
Electroencephalographic activity was recorded according to
recommended pharmaco-EEG standards (Knott, 2000; Saletu
et al., 2006; Jobert et al., 2012) while participants were seated
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reclined with eyes closed. Using an electronically linked mastoid
reference, Brain Vision R© Recorder software Version 2 (Brain
Products, Munich, Germany) was used to sample (1000 Hz)
electrical activity from 28 EEG and 2 (vertical and horizontal)
electrooculograpic (EOG) channels, with amplifiers/filters set
at 0.1–100 Hz, and with electrode impedance < 5 k. The
electrodes were divided into nine regions, including left frontal
(Fp1, F7, F3) middle frontal (Fz, FC1, FC2), right frontal (Fp2,
F4, F8), left temporal-central (T7, FC5, CP5), middle temporal-
central (C3, Cz, C4), right temporal-central (T8, FC6, CP6), left
posterior (P7, P3, O1), middle posterior (Pz, CP1, CP2), right
posterior (P4, P8, O2).
Scalp Surface CSD Analysis
Off-line processing with Brain Vision R© Analyzer 2 software
(Brain Products, Munich, Germany) involved: visual inspection
of recordings for elimination of activity with prominent
ocular/muscle/cardiac contamination or drowsiness (i.e., alpha
suppression combined with increased slow waves), ocular
correction of EEG with an algorithm (Gratton et al., 1983);
automatic rejection of activity with voltages > 100 uV and finally
application of independent component analysis (ICA) to remove
residual ocular (e.g., microsaccades) artifacts (McMenamin et al.,
2010). The resulting artifact-free recordings (minimum 120 s)
were transformed into reference-free CSD estimates using a
spherical Laplacian algorithm (Nunez et al., 1997; Mima and
Hallett, 1999). CSD estimates were computed using the fourth
order spherical spline interpolation, and a maximal degree of
Legendre polynomials of 10 (Perrin et al., 1989). Corrected,
non-overlapping 2-s epochs were subjected to a Fast Fourier
Transform algorithm (using a Hanning window with 10% taper
length) for computation of absolute CSD (averaged across epochs
at each electrode site) in delta (1–4 Hz), theta (4–8 Hz), alpha
(8–12.5 Hz), beta (12.5–30 Hz), and gamma (30–60 Hz) bands.
A natural log transform was applied to computed CSD values
(Gasser et al., 1982) and individual electrodes were aggregated to
create an average CSD value for anterior, temporal-central, and
posterior regions.
Source-Localized CSD Analysis
eLORETA (version 2081104) was used to compute the
intracortical source distribution of the electric activity from the
surface EEG data (Pascual-Marqui, 2011; Pascual-Marqui et al.,
2011). eLORETA is a weighted minimum non-linear inverse
solution method applied to EEG recordings for computation
of three dimensional distribution of electric cortical activity
with zero location error (Pascual-Marqui, 2011; Pascual-Marqui
et al., 2011). Localization with this methodology, even with
a lower number of electrodes used in this study has been
cross-validated with functional and structural MRI, PET and
intracranial recordings. Relying on the Montreal Neurologic
Institute average MRI brain (MNI 152) (Canuet et al., 2011) and
a solution space restricted to cortical gray matter/hippocampus,
eLORETA analysis of each EEG epoch results in current density
being computed at each of 6239 cortical voxels (5 mm spatial
resolution) for each of the frequency bands. Results were
averaged across epochs for each individual and frequency band
in placebo and ketamine sessions. Defined ROIs were based on
definitions of the Brodmann Areas (BA) provided by eLORETA
software package, which are based on the Talairach Daemon1.
A single voxel (at the centroid of each BA) was used for each ROI
due to eLORETA’s restricted spatial resolution, which makes it
unable to separate two closely spaced sources, and additionally,
the single centroid voxel (the closest to the center of the BA
mass) is an excellent representative of the corresponding BA.
The BAs comprising the representative hubs of the three targeted
networks within the TN model included: BA 11 (VMPFC), BA
23/30 (PCC), BA 9 (DLPFC), BA 40 (PPC), BA 24/32 (ACC), and
BA 47 (AI). CSDs were derived for left and right hemisphere of
each BA.
Statistics
Statistical analysis was conducted in SPSS 23 (SPSS Inc.,
Chicago, IL, USA). For each frequency band, scalp CSD values
were analyzed with a separate repeated measures analysis of
variance (ANOVA) involving treatment (placebo, ketamine),
region (anterior, temporal-central, posterior) and laterality (left,
middle, right) factors. Separate repeated measures ANOVAs were
also conducted for each band-indexed network and involved
treatment, hemisphere (left, right) and network hub (two levels)
factors. Significant (p< 0.05) Greenhouse-Geisser estimates were
followed up with Bonferroni adjusted T-test comparisons. The
three primary rating measures, depersonalization, derealisation
and observation, evidenced non-normal distributions and were
analyzed by the non-parametric Wilcoxon Signed Ranks Test
(WSRT). Relationships were examined with ketamine-induced
CSD and CADSS difference scores, obtained by subtracting
values in the placebo session from values in the ketamine
session, and analysis with the non-parametric Spearman’s
correlation coefficient. For source-localized EEG, these CADSS-
CSD relationships were separately examined for each hub of
each network. For scalp EEG, changes in CADSS were examined
in relation to the CSD averaged across the ketamine affected
electrode sites.
RESULTS
CADSS Rating Scores
The mean (±SE) values for the rating scores for the placebo
and ketamine conditions are displayed in Figure 1. Significant
increased self-ratings for amnesia (WSRT = −2.83, df = 1/40,
p < 0.005), depersonalization (WSRT = −3.53, df = 1/40,
p < 0.0001), and derealisation symptoms (WSRT = −3.36,
df = 1/40, p < 0.01) were shown for the ketamine compared to
placebo infusion condition. Ketamine also increased the observer
rated symptom scores (WSRT = −3.72, df = 1/40, p < 0.0001)
relative to placebo.
Scalp Surface CSD
As shown in Figure 2, scalp analyzed current density values
for slow and fast oscillations were significantly influenced by
1http://talairach.org/
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FIGURE 1 | Mean (±SE) Clinician Administered Dissociative States
Scale (CADSS) values for the rating scores for the placebo and
ketamine conditions (n = 21). ∗p < 0.05.
ketamine. Delta exhibited significant treatment (F = 6.14,
df = 1/20, p < 0.02) and treatment × region interaction effects
(F = 3.52, df = 2/40, p < 0.04), with ketamine acting to reduce
CSD bilaterally in temporal-central (p < 0.02) and posterior
(p < 0.01) regions. Within a treatment region × laterality
interaction (F = 3.77, df = 4/80, p < 0.007), theta CSD was
similarly reduced in the left (p < 0.04) and right (p < 0.03)
posterior cortex. Exhibiting treatment (F = 9.91, df = 1/40,
p < 0.005), treatment x region (F = 4.43, df = 2/40,
p < 0.02) and treatment × region × laterality interaction
effects (F = 4.35, df = 4/80, p < 0.003), alpha current density
was significantly diminished in left (p < 0.002) and right
(p < 0.01) anterior, middle (p < 0.006) and right (p < 0.004)
temporal-central, and posterior regions following ketamine
infusion. Beta current density was not affected by ketamine
treatment but significant treatment effects for gamma (F = 5.49,
df = 1/20, p < 0.03) showed that ketamine increased current
density of these oscillations across all scalp regions. Table 1
displays a summary of the regional effects of ketamine vs.
placebo.
Source-Localized CSD
Default Mode Network (DMN)
Significant ketamine effects on ROIs of the DMN are
shown in Figure 3. Analysis of delta yielded a significant
treatment × hemisphere interaction (F = 6.93, df = 1/20,
p < 0.007), with ketamine (vs. placebo) acting to reduce
CSD in the right hemisphere of the VMPFC and PCC
(p < 0.05). A significant treatment effect (F = 5.46,
df = 1/20, p < 0.03) showed general ketamine-induced
reductions in theta CSD across both hubs of the DMN.
Within treatment (F = 12.49, df = 1/20, p < 0.004) and
treatment × hub interaction effects (F = 5.58, df = 1/20,
p < 0.03), ketamine was found to diminish alpha CSD in the
PCC (p< 0.002).
In contrast with the other oscillatory bands, gamma
CSD was significantly increased by ketamine in both the
VMPFC and PCC hubs of the DMN (F = 5.72, df = 1/20,
p< 0.03).
FIGURE 2 | Grand averaged scalp current source density (CSD) topographic maps for the placebo and ketamine conditions for the frequency bands,
together with a spectral graph of gamma from the Cz site.
TABLE 1 | Summary of significant ketamine-induced scalp surface current source density (CSD) regional changes associated with each frequency band.
Delta Theta Alpha Beta Gamma
↓ Left, Right temporal-central ↓ Left, Right Posterior ↓ Left, Right Anterior No changes ↑ Left, Middle, Right Anterior
↓ Left, Right Posterior ↓ Middle, Right temporal-central ↑ Left, Middle, Right temporal-central
↓ Left, Middle, Right Posterior ↑ Left, Middle, Right Posterior
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FIGURE 3 | Mean (±SE) non-logged source-localized CSD values (A/m2) for the two regions of interest of the default mode network (n = 21).
∗p < 0.05. VMPFC, ventromedial prefrontal cortex; PCC, posterior cingulate cortex.
FIGURE 4 | Mean (±SE) non-logged source-localized CSD values (A/m2) for the two regions of interest of the central executive network (n = 21).
∗p < 0.05. DLPFC, dorsolateral prefrontal cortex; PPC, posterior parietal cortex.
Central Executive Network (CEN)
For both theta (F= 7.21, df= 1/20, p< 0.01) and alpha (F= 6.03,
df = 1/20, p < 0.02), significant treatment × region interactions
saw the CSD of these oscillations in the PPC to be reduced
by ketamine compared to placebo (Figure 4). No significant
treatment effects were observed for delta, beta or gamma CSD.
Salience Network (SN)
Whereas a significant overall treatment effect (F = 7.96,
df = 1/20, p < 0.01) showed alpha CSD to be reduced in both
ACC and AI hubs of the SN, a treatment x region interaction
evidenced with beta (F = 10.47, df = 1/20, p < 0.004) found
current density reductions to be limited to the ACC (p < 0.05).
Ketamine, by contrast, significantly (F = 4.85, df = 1/20,
p < 0.04) increased ACC and AI gamma current density
(Figure 5).
CADSS-CSD Relationships
Changes in symptoms induced by ketamine were significantly
associated with ketamine-induced changes in scalp and source-
localized EEG, but only with alpha CSD (Figure 6). Scalp EEG
alpha changes were negatively correlated with depersonalization
ratings (r = −0.58, p < 0.006). For source-localized EEG,
reductions in alpha CSD in the left (r = −0.66, p < 0.04) and
right (r = −0.64, p < 0.002) PCC hemispheres of the DMN,
and the right PPC (r = −0.54, p < 0.01) and AI hemispheres
(r = −0.45, p < 0.04) of the CEN and SN, respectively, were
related to increased depersonalization rating scores. No other
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FIGURE 5 | Mean (±SE) non-logged source-localized CSD values (A/m2) for the two regions of interest of the salience network (n = 21). ∗p < 0.05.
AI, anterior insula; ACC, anterior cingulate cortex.
correlations were evidences with delta, theta, beta, or gamma
rhythms.
DISCUSSION
Although there are plenty of single blind EEG/MEG studies,
this is the first randomized, placebo-controlled, double-blind
crossover study of healthy humans administered a sub-anesthetic,
psychotomimetic dose of ketamine that demonstrates changes
in resting-state EEG across the frequency spectrum. The work
builds on extensive animal research on the electrophysiological
effects of ketamine and well-studied EEG correlates of anesthetic
doses of ketamine. As key findings, we report CSD alterations
in low and high frequency rhythms analyzed from scalp EEG
recordings and these were accompanied by similar current
density changes in source-localized cortical ROIs within the three
large-scale networks of the schizophrenia model, namely the
DMN, CEN and SN. These electrocortical effects of ketamine
were paralleled by changes in dissociative states, the degree of
which was significantly correlated with scalp and SZ network
alpha current density changes.
N-methyl-D-aspartate receptor antagonism in preclinical
models has most frequently been associated with increases in
low (delta/theta) and high (beta/gamma) frequencies (Hunt and
Kasicki, 2013). These in vivo electrocortical findings with NMDA
receptor blockade, paralleled to some extent by oscillatory
changes in in vitro (Kim et al., 2015) recordings and intracortical
networks (Hakami et al., 2009), vary considerably, particularly
with respect to theta rhythms, which have also been shown to
be reduced both with acute and chronic ketamine treatment
(Kittelberger et al., 2012). Our EEG observations in healthy
volunteers of increased gamma and reduced non-gamma activity
with a ketamine dose typically used to model SZ in part
confirm previous independent study findings of EEG alpha
and gamma changes seen with anesthetic and sub-anesthetic
dosing in humans (Schultz et al., 1990; Kochs et al., 1996;
Knott et al., 2006; Bojak et al., 2013; Sanacora et al., 2014) and
they correspond with ketamine-induced alpha/beta and gamma
alterations in recent resting MEG studies (Muthukumaraswamy
et al., 2015; Rivolta et al., 2015). These emerging electrocortical
patterns with NMDA receptor blockade seen in our study and
in other investigations are reminiscent of some of the reports of
aberrant EEG activity in SZ. Deficits in resting spontaneous alpha
band activity reported across the clinical course of the disease
(chronic SZ, first episode psychosis, prodromal SZ, relatives of SZ
probrands) (Boutros et al., 2008; Goldstein et al., 2015; Kim et al.,
2015) were mimicked in our EEG recordings across scalp regions
following NMDA antagonist treatment. They were also seen
in recent MEG recordings (Muthukumaraswamy et al., 2015),
and were concurrent with diffuse increments in gamma also
described in some recent resting state studies of SZ (Kam et al.,
2013; Kocsis et al., 2013; Tikka et al., 2013, 2014, 2015). These
parallel observations with alpha and gamma spectral frequencies
contrast with the response of delta-theta and beta activities to
NMDA receptor blockade as the reduction in current density
with ketamine, particularly in the low frequencies, is contrary to
the observation that increased local and global EEG delta/theta
is one of the more consistent findings reported in unmedicated,
first episode, and chronic SZ patients (Boutros et al., 2008; Moran
and Hong, 2011; Kim et al., 2015).
Thus, acute NMDA receptor hypofunction may mediate some
of the EEG disturbances associated with psychosis, particularly
those relating to high frequency gamma perturbations, which
in this study likely result from ketamine inhibition of NMDA
receptors on GABA interneurons and disinhibition of pyramidal
neurons (Grunze et al., 1996; Maccaferri and Dingledine,
2002; Jackson et al., 2004; Homayoun and Moghaddam, 2007)
subpopulations, some of which act to increase cortical gamma
during inhibition (Lovett-Barron et al., 2012; Royer et al.,
Frontiers in Pharmacology | www.frontiersin.org 7 September 2016 | Volume 7 | Article 348
fphar-07-00348 September 24, 2016 Time: 15:39 # 8
de la Salle et al. Effects of Ketamine on Resting-State EEG Activity
FIGURE 6 | Scatterplots of significant ketamine-induced changes in scalp and source-localized EEG and changes in CADSS scores induced by
ketamine (n = 21). Scalp CSD scatterplots represent averaged values of significant regional changes.
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2012). Considering ketamine’s multitude of effects, with actions
at muscarinic, opioid, and adrenergic receptors and actions
blocking serotonin and norepinephrine transporters (Bergman,
1999; Chen et al., 2009; Stahl, 2013), any one or more of
these mechanisms [and/or the purported increase in non-NMDA
glutamate (i.e., AMPA and kainate) receptor neurotransmission
resulting from release of GABA restraint during impaired NMDA
receptor function (Olney and Farber, 1995; Moghaddam et al.,
1997)] may underly changes in non-gamma rhythms seen
in SZ and with acute NMDA receptor blockade. Given that
oxidative stress is thought to play a crucial role in several
brain disorders including psychosis (Sorce and Krause, 2009;
Schiavone et al., 2012, 2016), is involved in the modulation of
neuronal activity (Infanger et al., 2006), and is increased with
acute subanesthetic doses of ketamine and controls the resultant
prefrontal glutamate release accompanying NMDA receptor
antagonism (Sorce et al., 2010), brain oxidative stress may be
one novel mechanism underlying the SZ-like electrophysiological
changes with ketamine administration.
Contributing cortical sources to our observed ketamine
modulated EEG profile were examined within the TN model of
SZ. Although there is increasing interest in the pathophysiology
of brain networks in SZ, to our knowledge this is the first human
study to explore CSD in nodes of three well defined large-scale
neural networks during acute NMDA receptor hypofunction.
Directional changes in surface-level EEG current density induced
by ketamine within each frequency band were mirrored by
CSD alterations across the networks and, whereas only with
alpha CSD were all three networks shown to be affected by
NMDA receptor blockade, nodes of at least one or two of the
networks evidenced ketamine-induced changes in delta (DMN),
theta (DMN, CEN), beta (SN), and gamma (DMN, SN) rhythms.
Activity of individual high and low frequencies is associated with
both overlapped and distinct sensory and cognitive functions but
given the general observation that reductions in low frequency
and increases in high frequency rhythms are associated with
increased arousal and behavioral activation (Moran and Hong,
2011), our frequency specific oscillatory changes with ketamine
generally suggest that affected nodes within the respective large
scale networks are hyperactivated during NMDA antagonist
treatment. The exception is seen with the ACC, which showed
alpha reductions and gamma increases (activation) along with
decreases in beta (suppression) during ketamine administration.
This general pattern of cortical activation during waking states is
very similar to that reported in healthy volunteer studies utilizing
fMRI and PET to image resting cerebral blood flow and brain
metabolic response to ketamine’s blockade of NMDA receptors
(Lahti et al., 1995; Breier et al., 1997; Vollenweider et al., 1997;
Deakin et al., 2008; De Simoni et al., 2013; Doyle et al., 2013;
Scherbinin et al., 2015). Although there are discrepancies in these
neuroimaging studies, ketamine has typically activated frontal
and temporal lobe structures as well as the AI and PCC but
has suppressed the VMPFC while exhibiting mixed effects on
the ACC, which has been found to be either hyperactive or
hypoactive with acute antagonist treatment.
Accumulating neuroimaging evidence in healthy individuals
indicates that an imbalance between the normally anti-correlated
DMN (internal, self-related processing) and CEN (external
environment/task-related processing) may underlie clinical and
cognitive features of various psychiatric disorders (Menon, 2011),
including SZ (Northoff, 2015). Although aberrant glutamatergic
signaling in either the DMN or CEN may disrupt this balance,
the AI-ACC nodes of the SN network, and the AI in particular,
play a critical and causal role in the switch between activation
and deactivation of the two large-scale brain networks (Sridharan
et al., 2008). Structural and functional abnormalities across the
different stages of SZ occur in the nodes of SN (Palaniyappan
et al., 2012) and dopaminergic dysfunction in the SN is viewed
as having a central role in aberrant motivational salience (Kapur,
2003) and clinical symptoms (Palaniyappan and Liddle, 2012)
in individuals with psychosis. GABA/glutamate coupling is also
thought to mediate SN functions and subanesthetic doses of
ketamine have been specifically shown to increase glutamate
turnover in the ACC, consistent with studies in SZ in which
glutamatergic levels are elevated in the ACC of early-stage, drug
naïve or drug-free patients (Merritt et al., 2013; Poels et al., 2014).
Our findings of ketamine-induced increases in gamma in the
ACC and AI nodes, likely resulting from reduced excitation of
GABAergic interneurons and the subsequent disinhibition of
glutamatergic pyramidal neurons, may represent elevated noise
at pyramidal cell assemblies (Moran et al., 2015), which may
act to reduce high frequency signal-to-noise ratio in response
to sensory input (Saunders et al., 2012) and disrupt information
processing in these networks. Given that activity in the SN
typically precedes and predicts activity in both DMN and
CEN (Sridharan et al., 2008), implying that the SN coordinates
multi-networking activity, then alterations in gamma in the
SN may act to decrease the inherent anti-correlation between
the DMN and CEN, as suggested by the co-activation of
these networks, which is indexed by reductions in delta/theta
and alpha activity. Decreases in anti-correlation between the
DMN and CEN are thought to diminish the boundaries or
distinction between internally and externally oriented cognitions,
confusing internal and external mental contents and resulting in
“self-environment blurring” (Vollenweider et al., 1997) – thus
providing a mechanistic path that may explain several core
symptoms of SZ.
Oscillations generated by thalamocortical circuits are thought
to be responsible for the synchronization of neural activity
between different cortical regions and, depending on the
frequency range of the most prominent oscillation, are associated
with the appearance of specific mental states. Generally,
thalamocortically generated gamma is thought to be a potential
explanation for coherence of perception in the brain while alpha
serves to route information to downstream regions by inhibiting
neuronal processing in task-irrelevant regions (Jensen and
Mazaheri, 2010; Foxe and Snyder, 2011; Klimesch, 2012), thus
allowing task-relevant regions to communicate. Accordingly,
the reduction in alpha and increase in gamma seen in the SN
with acute ketamine may be associated with reduced salience
processing capabilities (due to impaired sensory/perceptual
functions) and diminished registration of salience below the
threshold that is needed to allow switching between the triple
networks.
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Study analysis of the subjective response to NMDA antagonist
treatment assessed with CADSS showed significant dissociative
effects, with ketamine infusion resulting in marked increases
in amnesia, depersonalization, derealisation, and objective rater
subscale scores. These dissociative phenomena, which have been
consistently reported in previous ketamine studies with healthy
volunteers and particularly in males (Morgan et al., 2006), are
part of a spectrum of transient SZ-like psychoactive effects
(including positive and negative symptoms) produced with acute
subanesthetic ketamine (Krystal et al., 1994; Malhotra et al.,
1996; Adler et al., 1998) and can be attenuated by inhibiting
the reuptake glycine, a co-agonist at the strychnine-insensitive
glycine-β site on the NMDA receptor (D’Souza et al., 2012).
Of the perceptual effects we observed with ketamine infusion,
only changes in depersonalization scores were related to the EEG
alterations. Increases in depersonalization ratings were associated
with reductions in alpha current density across the scalp and in
specific nodes of the DMN (bilateral PCC), CEN (right PPC),
and SN (right AI). Altered self-other boundary, experienced as
depersonalization (feeling detached as if one’s body is unreal),
is one of several so-called “basic symptoms” of prodromal SZ
(Maggini et al., 2002; Raballo, 2012). There is considerable
overlap in midline cortical structures comprising the neural
network implicated in self-specificity with those showing high
resting state in the DMN, and while evidence suggests that the
pregenual ACC is specifically involved in self-processing (Qin
and Northoff, 2011), several neuroimaging studies have also
pointed to the AI as being the representational cortex for the
sense of self (Craig, 2002, 2009). Alpha rhythms are considered
among the most important building blocks for functioning,
association and communication in the brain (Basar, 2012; Basar
and Guntekin, 2012; Bazanova and Vernon, 2014). Alpha is
prominent in the EEG DMN profile (Chen et al., 2008), overlaps
with resting-state networks identified in fMRI (Jann et al., 2007;
Mantini et al., 2007), and in addition to being the main neural
oscillation of self-agency (a person’s feeling that his action is
generated by himself; Kang et al., 2015), correlates with both
perception of self-related stimuli and resting state glutamate
concentration in the pregenual ACC (Bai et al., 2016). Given this
context, our findings with ketamine suggest that glutamatergic
modulated alpha activity may be one mechanism underlying
pathological self-processing in SZ and may serve as a viable target
for novel treatment interventions.
Limitations
The present results provide preliminary informative insight
into the some of the electrocortical mechanisms influenced by
blockade of NMDA receptors but limitations of the study must
also be considered. First, ketamine is one of the most selective
NMDA receptor antagonists available for human studies but it
has secondary sites of action unrelated to these glutamatergic
receptors and thus additional experiments with more selective
NMDA receptor antagonists are needed to specifically associate
our EEG findings to NMDA receptor hypofunction. Also, some of
the non-specific behavioral effects associated with ketamine (e.g.,
drowsiness) may have compromised the study blind, and future
studies may want to systematically document these behaviors to
determine how these potential confounds may impact statistical
analyses and data interpretation. Studies may also consider
incorporating into their design an active placebo comparator
drug such as midazolam, which has similar pharmacokinetic
properties, rapid anesthetic and behavioral effects as ketamine.
Further, acute NMDA antagonism reproduces many features of
SZ but others (auditory hallucination) appear only after chronic
administration (Javitt et al., 2012). The design of this study
does not explicitly allow for longitudinal inferences, but different
effects of short-and long-term exposure to NMDA antagonists
have been demonstrated for varying neurotransmitter systems
and cognitive domains (Bubeniková-Valesová et al., 2008). EEG
studies with animal models of chronic ketamine users are
required to profile the progression of these acute oscillatory
changes. Second, EEG has relatively low spatial resolution
compared to other imaging modalities such as fMRI. Future
multimodal studies may wish to combine EEG recordings with
concurrent fMRI or MEG recordings to further verify the
sources of EEG markers. Moreover, it may be advantageous
to implement ICA in the eLORETA software (eLORETA-ICA)
as ICA decomposition of EEG data becomes more correct in
localization and more robust to artifacts (Jonmohamadi et al.,
2014) and filtered ICA time series of EEG correlates with BOLD
time series in specific resting networks (Hiltunen et al., 2014).
For high frequencies, which may be contaminated by muscle
artifact, it would be useful to supplement this approach with
electromyographic recordings and to apply canonical correlation
analysis (CCA) as a blind source separation technique to remove
broadband or electromyographic noise from single EEG epochs
(De Clereq et al., 2006). These pre-processing strategies as well
as more recently recommended state-of-the-art methodologies
for analyzing high-frequency (gamma range) activity should be
adopted in future ketamine-EEG research (Jobert et al., 2012;
Nottage and Horder, 2015). As well, EEG assessments did
not include measures of synchronization to index oscillatory
coherence which may have been influenced by ketamine and may
have provided insight into the pattern of aberrant regional and
intra- and inter-network functional connectivity associated with
NMDA receptor antagonism. Third, the dynamic TN hypothesis
was not directly tested with experimental conditions that
would behaviourally challenge each specific network function.
Only dissociative symptoms were monitored and we did not
include assessments of positive, negative, or cognitive symptoms,
each of which may have been uniquely affected by ketamine
infusion and differentially associated with oscillatory alterations
resulting from NMDA receptor blockade. For example, beta
reductions in SN ACC hub with ketamine were not associated
with depersonalization ratings but, given that this oscillatory
frequency is predominantly in attention tasks, its dysfunction
with NMDA receptor blockade may be relevant to aberrant
salience processing.
CONCLUSION
In summary, resting-state EEG appears to be a useful and efficient
method for investigating the neuropharmacology of altered brain
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rhythms suspected to underlie perceptual/dissociative symptoms
of SZ. In the present study, sensor-level and surface projected
neural network electrocortical activity was investigated in a
NMDA receptor hypofunction model of SZ and intravenous
ketamine was shown to partly mimic the aberrant EEG activity
observed in SZ patients and to alter oscillations in large-scale
resting-state networks implicated in psychosis. Neuroelectric
changes correlated with the severity of dissociative symptoms
induced by NMDA receptor antagonist treatment. Together,
these findings provide additional information on how the
modulation of the glutamatergic system may regulate brain
electric activity, supporting its potential utility both as a
biomarker of NMDA receptor dysfunction and a possible target
for novel treatments in psychiatric disorders such as SZ which
involve glutamatergic deficits.
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